Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Personalized Medicine
Personalized Medicine
Articles about personalized medicine on Value-Based Cancer Care. Learn how to utilize a patient's unique genetic makeup and environment to customize the patient's medical care and treatment.
Filter by Topic
Cancer Care
Cancer Drugs
Cancer Prevention
Cancer Quick Takes
Cancer Rehabilitation
Cancer Screening
Cervical Cancer
Chemotherapy
Clinical Research
Clinical Trials
Emerging Therapies
Genetic Testing
Hematologic Malignancies
Hormone Therapy
Immunotherapy
Multidisciplinary Care
Palliative Care
Pregnancy & Cancer
Prognostic Tests
Radiation Therapy
Radiotherapy in Focus
Sentinel Node Management
Solid Tumors
Liquid Biopsies Show High Correlation with Tissue Biopsy for Genetic Mutations
By
Wayne Kuznar
Personalized Medicine
July 2016, Vol 7, No 6
With the exception of resistance mutations, somatic alterations in circulating tumor (ct) DNA (ie, a liquid biopsy) are consistent with alterations found in tissue biopsies of patients with advanced solid tumors, said Philip C. Mack, PhD, Director of Molecular Pharmacology, University of California Davis Comprehensive Cancer Center, Sacramento, at the 2016 American Society of Clinical Oncology (ASCO) annual meeting.
Read Article
ESR1 Mutations Predict Worse Survival in ER-Positive Advanced Breast Cancer
By
Phoebe Starr
Personalized Medicine
June 2016, Vol 7, No 5
A “liquid biopsy” was able to detect 2 mutations in the
ESR1
gene that predicted worse overall survival (OS) in women with estrogen receptor (ER)-positive metastatic breast cancer who were originally enrolled in the phase 3 BOLERO-2 clinical trial, according to results presented at the 2015 San Antonio Breast Cancer Symposium.
Read Article
Promising Antitumor Activity of ODM-201 in Metastatic Prostate Cancer
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
June 2016, Vol 7, No 5
Read Article
Chemotherapy Use in Breast Cancer Declines with Gene-Based Assay
By
Charles Bankhead
Chemotherapy
,
Value in Oncology
,
Personalized Medicine
June 2016, Vol 7, No 5
Women with clinicopathologic high-risk breast cancer had nearly a 50% reduction in prescription chemotherapy, with no increased risk for metastatic recurrence when a cancer gene-based assay was used to guide treatment decision-making, according to new data presented at the 2016 American Association for Cancer Research meeting.
Read Article
Mutation Testing Encouraged for All Patients with Ovarian Cancer
By
Charles Bankhead
Personalized Medicine
June 2016, Vol 7, No 5
Read Article
Entrectinib Shows Strong Activity Against a Range of Rare Solid Tumors with Molecular Abnormalities
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
June 2016, Vol 7, No 5
Read Article
How Do We Measure Quality in the Age of Precision Medicine? Stakeholder Perspectives
By
Meg Barbor, MPH
Personalized Medicine
May 2016, Vol 7, No 4
Assessing quality care in the age of precision medicine can be challenging. In a special session at the 2016 Quality Care Symposium, various stakeholders presented their perspectives on the challenges and opportunities related to quality care in this rapidly changing landscape.
Read Article
Biomarker for Uveal Melanoma Has Immediate Clinical Impact
By
Phoebe Starr
Personalized Medicine
April 2016, Vol 7, No 3
A new biomarker can identify the subgroup of class 1 uveal melanomas that are most likely to metastasize, according to a new retrospective study (Field MG, et al.
Clin Cancer Res
. 2016;22:1234-1242).
Read Article
Genomics May Explain Poor Survival of African Americans with Kidney Cancer
By
Phoebe Starr
Personalized Medicine
April 2016, Vol 7, No 3
Differences in 3 recently identified molecular factors in patients with metastatic renal-cell carcinoma (RCC) may explain the inferior survival rates in African-American patients versus in Caucasian patients, even in the age of targeted therapy.
Read Article
Venetoclax Shows Strong Activity in CLL
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
February 2016, Vol 7, No 1
The oral, investigational, small-molecule BCL-2 inhibitor venetoclax has shown excellent and durable responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). All patients in the trial harbored the 17p deletion (del 17p), which signals poor prognosis.
Read Article
Page 15 of 35
10
11
12
13
14
15
16
17
18
19
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma